• SEC Filings

On November 28, 2016, Biocept, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company had failed to comply with the $1.00 per share minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). On January 24, 2017, the Company received a letter from Nasdaq indicating that, because the Company’s common stock has had a minimum closing bid price of at least $1.00 per share for at least 10 consecutive business days, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

About BIOCEPT, INC. (NASDAQ:BIOC)

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

BIOCEPT, INC. (NASDAQ:BIOC) Recent Trading Information

BIOCEPT, INC. (NASDAQ:BIOC) closed its last trading session down -0.06 at 1.63 with 2,143,219 shares trading hands.